Conformational ensembles, signal transduction and residue hot spots: Application to drug discovery

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 5, 2010, Pages 527-537

  Ozbabacan, Saliha Ece Acuner ^a   Gursoy, Attila ^a   Keskin, Ozlem ^a   Nussinov, Ruth ^b,c  

^a KOÇ UNIVERSITY   (Turkey)

^b SAIC FREDERICK INC   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allosteric; cellular pathway; conformational selection; drug design; drug target; molecular recognition; pharmacological research; protein dynamics; protein network; signaling

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; B7 ANTIGEN; BENZODIAZEPINEDIONE; NUTLIN 2; NUTLIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN P53; RO 26 4550; RP 26 4550; SP 4160; SP 4206; UNCLASSIFIED DRUG; WORTMANNIN;

CONFORMATIONAL TRANSITION; DNA BINDING; DRUG BINDING SITE; DRUG RESEARCH; DRUG TARGETING; HUMAN; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; ONCOGENE H RAS; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC SITE; ANIMALS; DNA-BINDING PROTEINS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956398004     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Alberts B, Bray D, Hopkin K, Johnson A, Lewis J, Raff M, Roberts K, Walter P (Eds): Essential Cell Biology. Garland Science, New York, NY, USA (2009).
2. Bhattacharyya RP, Remenyi A, Yeh BJ, Lim WA: Domains, motifs, and scaffolds: The role of modular interactions in the evolution and wiring of cell signaling circuits. Annu Rev Biochem (2006) 75:655-680.
3. Bhattacharyya RP, Remenyi A, Good MC, Bashor CJ, Falick AM, Lim WA: The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. Science (2006) 311(5762):822-826.
4. Dill KA: Polymer principles and protein folding. Protein Sci (1999) 8(6):1166-1180.
5. Frauenfelder H, Sligar SG, Wolynes PG: The energy landscapes and motions of proteins. Science (1991) 254(5038):1598-1603.
6. Tsai CJ, del Sol A, Nussinov R: Protein allostery, signal transmission and dynamics: A classification scheme of allosteric mechanisms. Mol Biosyst (2009) 5(3):207-216.
7. Ma B, Kumar S, Tsai CJ, Nussinov R: Folding funnels and binding mechanisms. Protein Eng (1999) 12(9):713-720.
8. Tsai CJ, Kumar S, Ma B, Nussinov R: Folding funnels, binding funnels, and protein function. Protein Sci (1999) 8(6):1181-1190.
9. Tsai CJ, Ma B, Nussinov R: Folding and binding cascades: Shifts in energy landscapes. Proc Natl Acad Sci USA (1999) 96(18):9970-9972.
10. del Sol A, Tsai CJ, Ma B, Nussinov R: The origin of allosteric functional modulation: Multiple pre-existing pathways. Structure (2009) 17(8):1042-1050.
11. Gunasekaran K, Ma B, Nussinov R: Is allostery an intrinsic property of all dynamic proteins? Proteins (2004) 57(3): 433-443.
12. Volkman BF, Lipson D, Wemmer DE, Kern D: Two-state allosteric behavior in a single-domain signaling protein. Science (2001) 291(5512):2429-2433.
13. White AW, Westwell AD, Brahemi G: Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev Mol Med (2008) 10:e8.
14. Blazer LL, Neubig RR: Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: Current progress and future hurdles. Neuropsychopharmacology (2009) 34(1):126-141.
15. Siehler S: Cell-based assays in GPCR drug discovery. Biotechnol J (2008) 3(4):471-483.
16. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov (2002) 1(9):727-730.
17. Jones S, Thornton JM: Principles of protein-protein interactions. Proc Natl Acad Sci USA (1996) 93(1):13-20.
18. Ofran Y, Punta M, Schneider R, Rost B: Beyond annotation transfer by homology: Novel protein-function prediction methods to assist drug discovery. Drug Discov Today (2005) 10(21):1475-1482.
19. Keskin O, Gursoy A, Ma B, Nussinov R: Towards drugs targeting multiple proteins in a systems biology approach. Curr Top Med Chem (2007) 7(10):943-951.
20. Arkin MR, Wells JA: Small-molecule inhibitors of proteinprotein interactions: Progressing towards the dream. Nat Rev Drug Discov (2004) 3(4):301-317.
21. Clackson T, Wells JA: A hot spot of binding energy in a hormone-receptor interface. Science (1995) 267(5196):383-386.
22. Bogan AA, Thorn KS: Anatomy of hot spots in protein interfaces. J Mol Biol (1998) 280(1):1-9.
23. Thorn KS, Bogan AA: ASEdb: A database of alanine mutations and their effects on the free energy of binding in protein interactions. Bioinformatics (2001) 17(3):284-285.
24. Hu Z, Ma B, Wolfson H, Nussinov R: Conservation of polar residues as hot spots at protein interfaces. Proteins (2000) 39(4):331-342.
25. Keskin O, Ma B, Nussinov R: Hot regions in protein-protein interactions: The organization and contribution of structurally conserved hot spot residues. J Mol Biol (2005) 345(5): 1281-1294.
26. Moreira IS, Fernandes PA, Ramos MJ: Hot spots - A review of the protein-protein interface determinant amino-acid residues. Proteins (2007) 68(4):803-812.
27. Ma B, Elkayam T, Wolfson H, Nussinov R: Protein-protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci USA (2003) 100(10):5772-5777.
28. Cukuroglu E, Gursoy A, Keskin O: Analysis of hot region organization in hub proteins. Ann Biomed Eng (2010) 38(6): 2068-2078.
29. Tuncbag N, Salman FS, Keskin O, Gursoy A: Analysis and network representation of hotspots in protein interfaces using minimum cut trees. Proteins (2010) 78(10):2283-2294.
30. Reichmann D, Cohen M, Abramovich R, Dym O, Lim D, Strynadka NC, Schreiber G: Binding hot spots in the TEM1-BLIP interface in light of its modular architecture. J Mol Biol (2007) 365(3):663-679.
31. Reichmann D, Rahat O, Albeck S, Meged R, Dym O, Schreiber G: The modular architecture of protein-protein binding interfaces. Proc Natl Acad Sci USA (2005) 102(1):57-62.
32. Moza B, Buonpane RA, Zhu P, Herfst CA, Rahman AK, McCormick JK, Kranz DM, Sundberg EJ: Long-range cooperative binding effects in a T cell receptor variable domain. Proc Natl Acad Sci USA (2006) 103(26):9867-9872.
33. DeLano WL, Ultsch MH, de Vos AM, Wells JA: Convergent solutions to binding at a protein-protein interface. Science (2000) 287(5456):1279-1283.
34. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å. Science (1996) 273(5274):464-471.
35. Sidhu SS, Lowman HB, Cunningham BC, Wells JA: Phage display for selection of novel binding peptides. Methods Enzymol (2000) 328:333-363.
36. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science (1996) 273(5274):458-464.
37. Wells JA, McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 450(7172):1001-1009.
38. Conn PJ, Christopoulos A, Lindsley CW: Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 8(1):41-54.
39. May LT, Leach K, Sexton PM, Christopoulos A: Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2007) 47:1-51.
40. Tsai CJ, Ma B, Sham YY, Kumar S, Nussinov R: Structured disorder and conformational selection. Proteins (2001) 44(4): 418-427.
41. Keskin O: Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: A case study of antibodies. BMC Struct Biol (2007) 7:31.
42. Tobi D, Bahar I: Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci USA (2005) 102(52):18908-18913.
43. Boehr DD, Nussinov R, Wright PE: The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol (2009) 5(11):789-796.
44. Tsai CJ, del Sol A, Nussinov R: Allostery: Absence of a change in shape does not imply that allostery is not at play. J Mol Biol (2008) 378(1):1-11.
45. James LC, Roversi P, Tawfik DS: Antibody multispecificity mediated by conformational diversity. Science (2003) 299(5611):1362-1367.
46. Rajamani D, Thiel S, Vajda S, Camacho CJ: Anchor residues in protein-protein interactions. Proc Natl Acad Sci USA (2004) 101(31):11287-11292.
47. Smith GR, Sternberg MJ, Bates PA: The relationship between the flexibility of proteins and their conformational states on forming protein-protein complexes with an application to protein-protein docking. J Mol Biol (2005) 347(5):1077-1101.
48. Yogurtcu ON, Erdemli SB, Nussinov R, Turkay M, Keskin O: Restricted mobility of conserved residues in protein-protein interfaces in molecular simulations. Biophys J (2008) 94(9): 3475-3485.
49. Tuncbag N, Kar G, Gursoy A, Keskin O, Nussinov R: Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: The p53 example. Mol Biosyst (2009) 5(12):1770-1778.
50. Kar G, Gursoy A, Keskin O: Human cancer protein-protein interaction network: A structural perspective. PLoS Comput Biol (2009) 5(12):e1000601.
51. Kim PM, Lu LJ, Xia Y, Gerstein MB: Relating three-dimensional structures to protein networks provides evolutionary insights. Science (2006) 314(5807):1938-1941.
52. Aytuna AS, Gursoy A, Keskin O: Prediction of proteinprotein interactions by combining structure and sequence conservation in protein interfaces. Bioinformatics (2005) 21(12):2850-2855.
53. Ogmen U, Keskin O, Aytuna AS, Nussinov R, Gursoy A: PRISM: Protein interactions by structural matching. Nucleic Acids Res (2005) 33(Web Server issue):W331-W336.
54. Shatsky M, Nussinov R, Wolfson HJ: A method for simultaneous alignment of multiple protein structures. Proteins (2004) 56(1):143-156.
55. Tuncbag N, Gursoy A, Keskin O: Identification of computational hot spots in protein interfaces: Combining solvent accessibility and inter-residue potentials improves the accuracy. Bioinformatics (2009) 25(12):1513-1520.
56. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A: The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science (1997) 277(5324):333-338.
57. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J: The structural basis of the activation of Ras by Sos. Nature (1998) 394(6691):337-343.
58. Humphrey W, Dalke A, Schulten K: VMD: Visual molecular dynamics. J Mol Graph (1996) 14(1):33-38, 27-38.
59. Carbonell P, Nussinov R, del Sol A: Energetic determinants of protein binding specificity: Insights into protein interaction networks. Proteomics (2009) 9(7):1744-1753.
60. Filchtinski D, Sharabi O, Rppel A, Vetter IR, Herrmann C, Shifman JM: What makes Ras an efficient molecular switch: A computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf. J Mol Biol (2010) 399(3):422-435.
61. Huang PS, Love JJ, Mayo SL: A de novo designed protein protein interface. Protein Sci (2007) 16(12):2770-2774.
62. Fromer M, Shifman JM: Tradeoff between stability and multispecificity in the design of promiscuous proteins. PLoS Comput Biol (2009) 5(12):e1000627.
63. Mandell DJ, Kortemme T: Computer-aided design of functional protein interactions. Nat Chem Biol (2009) 5(11):797-807.
64. Alonso H, Bliznyuk AA, Gready JE: Combining docking and molecular dynamic simulations in drug design. Med Res Rev (2006) 26(5):531-568.
65. London N, Movshovitz-Attias D, Schueler-Furman O: The structural basis of peptide-protein binding strategies. Structure (2010) 18(2):188-199.
66. Clackson T, Ultsch MH, Wells JA, de Vos AM: Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol (1998) 277(5):1111-1128.
67. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Post-translational modifications and regulation of the Ras superfamily of GTPases as anticancer targets. Nat Rev Drug Discov (2007) 6(7):541-555.
68. Tesmer JJ: Pharmacology. Hitting the hot spots of cell signaling cascades. Science (2006) 312(5772):377-378.
69. Stein A, Aloy P: Contextual specificity in peptide-mediated protein interactions. PLoS One (2008) 3(7):e2524.
70. Austin RJ, Ja WW, Roberts RW: Evolution of class-specific peptides targeting a hot spot of the Gαs subunit. J Mol Biol (2008) 377(5):1406-1418.
71. Emerson SD, Palermo R, Liu CM, Tilley JW, Chen L, Danho W, Madison VS, Greeley DN, Ju G, Fry DC: NMR characterization of interleukin-2 in complexes with the IL-2Rα receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Rα interaction. Protein Sci (2003) 12(4): 811-822.
72. Thanos CD, DeLano WL, Wells JA: Hot-spot mimicry of a cytokine receptor by a small molecule. Proc Natl Acad Sci USA (2006) 103(42):15422-15427.
73. Erbe DV, Wang S, Xing Y, Tobin JF: Small molecule ligands define a binding site on the immune regulatory protein B7.1. J Biol Chem (2002) 277(9):7363-7368.
74. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM et al: Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-XL. J Med Chem (2007) 50(4):641-662.
75. Levine AJ, Hu W, Feng Z: The p53 pathway: What questions remain to be explored? Cell Death Differ (2006) 13(6):1027-1036.
76. Picksley SM, Vojtesek B, Sparks A, Lane DP: Immunochemical analysis of the interaction of p53 with Mdm2; - Fine mapping of the Mdm2 binding site on p53 using synthetic peptides. Oncogene (1994) 9(9):2523-2529.
77. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N et al: In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science (2004) 303(5659):844-848.
78. Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F: NMR structure of a complex between Mdm2 and a small molecule inhibitor. J Biomol NMR (2004) 30(2):163-173.
79. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D et al: Discovery and cocrystal structure of benzodiazepinedione Hdm2 antagonists that activate p53 in cells. J Med Chem (2005) 48(4):909-912.
80. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the Mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 274(5289):948-953. (Pubitemid 26398409)
81. Norman BH, Shih C, Toth JE, Ray JE, Dodge JA, Johnson DW, Rutherford PG, Schultz RM, Worzalla JF, Vlahos CJ: Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem (1996) 39(5): 1106-1111.
82. Gabelli SB, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM: Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug design. Biochim Biophys Acta (2010) 1804(3):533-540.
83. Humphries MJ: Integrin structure. Biochem Soc Trans (2000) 28(4):311-339.
84. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol (1999) 292(1):1-9.
85. Kelly TA, Jeanfavre DD, McNeil DW, Woska JR Jr, Reilly PL, Mainolfi EA, Kishimoto KM, Nabozny GH, Zinter R, Bormann BJ, Rothlein R: Cutting edge: A small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol (1999) 163(10): 5173-5177.
86. Ohtsuka M, Konno F, Honda H, Oikawa T, Ishikawa M, Iwase N, Isomae K, Ishii F, Hemmi H, Sato S: PPA250 [3-(2,4- difluorophenyl)-6-[2-[4-(1H-imidazol- 1-ylmethyl) phenoxy] ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. J Pharmacol Exp Ther (2002) 303(1):52-57.
87. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA, Erickson S et al: Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA (2000) 97(4):1506-1511.
88. Chao M, Casaccia-Bonnefil P, Carter B, Chittka A, Kong H, Yoon SO: Neurotrophin receptors: Mediators of life and death. Brain Res Brain Res Rev (1998) 26(2-3):295-301.
89. Ibanez CF, Ebendal T, Barbany G, Murray-Rust J, Blundell TL, Persson H: Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the TRK gene product. Cell (1992) 69(2):329-341.
90. Niederhauser O, Mangold M, Schubenel R, Kusznir EA, Schmidt D, Hertel C: NGF ligand alters NGF signaling via p75NTR and TrkA. J Neurosci Res (2000) 61(3):263-272.
91. Colquhoun A, Lawrance GM, Shamovsky IL, Riopelle RJ, Ross GM: Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4- methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2- carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. J Pharmacol Exp Ther (2004) 310(2):505-511.
92. Eibl JK, Chapelsky SA, Ross GM: Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J Pharmacol Exp Ther (2010) 332(2): 446-454.
93. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ: Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J (2002) 21(14):3863-3872.
94. Gorina S, Pavletich NP: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 274(5289):1001-1005. (Pubitemid 26398426)